Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944319 | 0.91 | GPR119 (0.41) | GPR119BACE1ALDH1A1KDM1ACTSD | |
| SCHEMBL3114724 | 0.90 | BACE1 (0.39) | SLC2A1GPR119BACE1ALDH1A1KDM1A | |
| SCHEMBL3101367 | 0.89 | ALDH1A1 (0.41) | BACE1ALDH1A1KDM1ACTSDCTSE | |
| SCHEMBL3106664 | 0.87 | ALDH1A1 (0.45) | GPR119BACE1HDAC1ALDH1A1KDM1A | |
| SCHEMBL1945933 | 0.87 | KDM1A (0.39) | SLC2A1GPR119BACE1ALDH1A1KDM1A | |
| SCHEMBL1944513 | 0.87 | SRC (0.37) | GPR119ALOX5APFEN1BACE1ALDH1A1 | |
| SCHEMBL1944514 | 0.87 | SRC (0.37) | GPR119ALOX5APFEN1BACE1ALDH1A1 | |
| SCHEMBL1944532 | 0.86 | CHEK2 (0.38) | KDM1ACHEK2SRC | |
| SCHEMBL1944531 | 0.86 | CHEK2 (0.38) | KDM1ACHEK2SRC | |
| SCHEMBL3097478 | 0.86 | KDM1A (0.41) | GPR119ALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2193130-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009033084-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | SLC2A1 1976/4885GPR119 420/4885ALOX5AP 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.